Mechanism of rethrombosis after thrombolytic therapy: Angioscopic findings and investigation of the coagulation system in dogs

Angiology

Volumn 49, Issue 6, 1998, Pages 447-453

  Maki, Akira ^a   Shirato, Chiaki ^a   Ohguchi, Masahisa ^a   Aoki, Nobuo ^a   Ochiai, Nobuhiko ^a   Taguchi, Shigeru ^a   Aoki, Isao ^a   Ishikawa, Kyozo ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; ALTEPLASE; FIBRINOLYTIC AGENT; PLASMIN; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ANGIOSCOPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY ENDOTHELIUM; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DOG; FEMALE; FIBRINOLYTIC THERAPY; INTRACAVERNOUS DRUG ADMINISTRATION; MALE; NONHUMAN; RECURRENT DISEASE; THROMBOGENESIS;

EID: 0031799150     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331979804900605     Document Type: Article

References (17)

1. Schaer DH, Ross AM, Wasserman AG: Reinfarction, recurrent angina, and reocclusion after thrombolytic therapy. Circulation 76(suppl):II57-II62, 1987.
2. Bang NU, Wilhelm OG, dayman MD: After coronary thrombolysis and reperfusion, what next? J Am Coll Cardiol 14:837-849, 1989.
3. Neuhaus K-L, Tebbe U, Gottwik M, et al: Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: Results of the German Activator Urokinase Study (GAUS). J Am Coll Cardiol 12:581-587, 1988.
4. Califf RM, Topol EJ, George BS, et al: Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I Trial. Circulation 77: 1090-1099, 1988.
5. Ohman EM, Califf RM, Topol EJ, et al: Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 82:781-791, 1990.
6. Seitz R, Blanke H, Pratorius G, et al: Increased thrombin activity during thrombolysis. Thromb Haemost 59:541-542, 1988.
7. Gulba DC, Barthels M, Westhoff-Bleck M, et al: Increased thrombin level during thrombolytic therapy in acute myocardial infarction: Relevance for the success of therapy. Circulation 83:937-944, 1991.
8. Francis CW, MarKham RE, Barlow GH, et al: Thrombin activity of fibrin thrombi and soluble plasmin derivatives. J Lab Clin Med 102:220-230, 1983.
9. Rao AK, Pratt C, Berke A, et al: Hemorrhagic manifestations and changes in plasma fibrinogen and fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11:1-11, 1988.
10. GISSI group: Cerebrovascular events after myocardial infarction: Analysis of the GISSI trial. Br Med J 302:1428-1431, 1991.
11. Matsuo O, Rijken DC, Collen D: Comparison of the relative fibrinogenolytic, fibrinolytic properties of tissue plasminogen activator and urokinase in vitro. Thromb Haemost 45:225-229, 1981.
12. Seiz R, Blanke H, Pratoris G, et al: Increased thrombin activity during thrombolysis. Thromb Haemost 59:541-542, 1988.
13. Lee CD, Mann KD: Activation/inactivation of human factor V by plasmin. Blood 73:185-190, 1988.
14. Winters KJ, Santro SA, Miletich JP, et al: Relative importance of thrombin compared with plasmin-mediated platelet activation in response to plasminogen activation with streptokinase. Circulation 84:1552-1560, 1991.
15. Verstraete M, Bory M, Collen D, et al: Randomized trial of intravenous recombinant tissue type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1:842, 1985.
16. Antman EM, TIMI 9A Investigators: Hirudin in acute myocardial infarction: Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 90:1625-1630, 1994.
17. Neuhaus KL, Essen RV, Tebbe U, et al: Safety observation from the pilot phase of the randomized rhirudin for improvement of thrombolysis (HIT-III) study. Circulation 90:1638-1642, 1994.